Olanzapine Reversed THC-Induced Memory Impairment in Rats, but Haloperidol Did Not | Research

The takeaway

The atypical antipsychotic olanzapine reversed THC's memory-impairing effects in rats by restoring acetylcholine levels in the hippocampus, while the older antipsychotic haloperidol had no effect.

Read this if you're interested in how antipsychotic medications interact with cannabis effects on memory.

Olanzapine reversed THC memory impairment; haloperidol did not at any dose

What the researchers found

Researchers tested whether two different antipsychotic medications could reverse the spatial memory impairment caused by THC in rats using an eight-arm radial maze.

THC (6 mg/kg) impaired spatial memory and decreased acetylcholine (ACh) levels in the dorsal hippocampus, a brain region critical for spatial memory.

Olanzapine (0.1 mg/kg), an atypical antipsychotic, reversed both the memory deficit and the acetylcholine decrease caused by THC. Haloperidol (0.03-0.3 mg/kg), a typical antipsychotic, had no effect on either measure at any dose tested.

The results suggest olanzapine's ability to restore hippocampal acetylcholine release may underlie its reversal of THC-induced cognitive impairment, potentially relevant to treating cannabis-related cognitive effects in patients with psychosis.

Why it matters

Many patients with schizophrenia use cannabis, which can worsen their cognitive symptoms. This study suggested that olanzapine (but not haloperidol) may counteract cannabis-induced cognitive impairment, potentially guiding antipsychotic selection for cannabis-using patients.

The numbers in context

THC dose: 6 mg/kg. Olanzapine 0.1 mg/kg reversed memory deficits and ACh decrease. Haloperidol 0.03-0.3 mg/kg had no effect. THC decreased ACh in dorsal hippocampus.

How the study worked

Rats were tested in an eight-arm radial maze task after receiving THC (6 mg/kg i.p.) with or without olanzapine or haloperidol pretreatment. Extracellular acetylcholine levels in the dorsal hippocampus were measured by in vivo microdialysis.

What this study cannot tell us

Rat spatial memory tasks may not translate to human cognitive function. The THC dose was relatively high. Only one dose of olanzapine was effective. The clinical relevance for humans requires clinical trial confirmation.

How to read the evidence

This is an animal study with clear results but limited clinical translatability. The single effective olanzapine dose and artificial setting limit generalization.

When this study was published

Published in 2008. Research on antipsychotic-cannabis interactions has continued, with growing clinical interest in optimizing treatment for cannabis-using psychosis patients.

The bigger picture

The distinction between atypical (olanzapine) and typical (haloperidol) antipsychotics in reversing THC effects reflects their different pharmacological profiles. Olanzapine's broader receptor activity, including effects on cholinergic systems, may make it more suitable for cannabis-using patients with psychosis.

Questions still open

Do atypical antipsychotics produce better cognitive outcomes in cannabis-using schizophrenia patients? Could olanzapine-like mechanisms be exploited to treat cannabis-induced cognitive impairment without the metabolic side effects of olanzapine?

Common questions

Why does olanzapine work but not haloperidol?

Olanzapine affects a wider range of brain chemical systems than haloperidol, including the cholinergic (acetylcholine) system. Since THC impairs memory partly by reducing acetylcholine, olanzapine's ability to boost acetylcholine may be the key difference.

Does this mean olanzapine protects against cannabis effects in humans?

This was a rat study and cannot directly predict human outcomes. However, it suggests a mechanism that could be tested in clinical studies of antipsychotic choice for cannabis-using patients.

Read the original research

Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.

Progress in neuro-psychopharmacology & biological psychiatry, 32(2), 499-506

View on PubMed ↗

Citation

Egashira, Nobuaki; Ishigami, Noriko; Mishima, Kenichi; Iwasaki, Katsunori; Oishi, Ryozo; Fujiwara, Michihiro. (2008). Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.. Progress in neuro-psychopharmacology & biological psychiatry, 32(2), 499-506.